The ultimate goal of curative anti-cancer therapies: Inducing an adaptive anti-tumor immune response

Frontiers in Immunology

Volumn 2, Issue DEC, 2011, Pages

  Fridman, Wolf H ^a,b,c   Teillaud, Jean Luc ^a,b   Sautès Fridman, Catherine ^a,b   Pagès, Franck ^a,b   Galon, Jérôme ^a,b,c   Zucman Rossi, Jessica ^b,c,d   Tartour, Eric ^b,c,d,e   Zitvogel, Laurence ^f,g,h   Kroemer, Guido ^a,b,c,d,f,i  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CBT 507 Centre of Clinical Investigations   (France)

^h UNIVERSITÉ PARIS SACLAY   (France)

ⁱ Institut Gustave Roussy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872617136     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2011.00066     Document Type: Article

References (45)

1. Abès, R., Gélizé, E., Fridman, W. H., and Teillaud, J. L. (2010). Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116, 926-934.
2. Abès, R., and Teillaud, J. L. (2011). Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev. 30, 111-124.
3. Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., Mejean, A., Fridman, W. H., Oudard, S., and Tartour, E. (2010). A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33, 991-998.
4. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F. J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J. P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., André, F., Delaloge, S., Tursz, T., Kroemer, G., and Zitvogel, L. (2007). Toll-like recep-tor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059.
5. Ashfaq, K., Yahaya, I., Hyde, C., Andronis, L., Barton, P., Bayliss, S., and Chen, Y. F. (2010). Clinical effective-ness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol. Assess. (Rockv.) 14, iii-iv, ix-xi, 1-141.
6. Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., Brasnu, D. F., and Tartour, E. (2006). Prognostic value of tumor-infil-trating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12, 465-472.
7. Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., Besmer, P., Guo, T., Antonescu, C. R., Taguchi, T., Yuan, J., Wolchok, J. D., Allison, J. P., and Dematteo, R. P. (2011). Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17, 1094-1100.
8. Beer, T. M., Bernstein, G. T., Corman, J. M., Glode, L. M., Hall, S. J., Poll, W. L., Schellhammer, P. F., Jones, L. A., Xu, Y., Kylstra, J. W., and Frohlich, M. W. (2011). Randomized trial of autologous cellular immuno-therapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res. 17, 4558-4567.
9. Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., and Banham, A. H. (2006). High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in fol-licular lymphoma. Blood 108, 2957-2964.
10. Carter, P. (2006). Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357.
11. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., and Ravetch, J. V. (1998). Fc receptors are required in pas-sive and active immunity to melanoma. Proc. Natl. Acad. Sci. U.S.A. 95, 652-656.
12. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M. L., Knutson, K. L., Chen, L., and Zou, W. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949.
13. Disis, M. L. (2010). Immune regulation of cancer. J. Clin. Oncol. 28, 4531-4538.
14. Finn, O. J. (2008). Cancer immunology. N. Engl. J. Med. 358, 2704-2715.
15. Fridman, W. H., Galon, J., Dieu-Nosjean, M. C., Cremer, I., Fisson, S., Damotte, D., Pagès, F., Tartour, E., and Sautès-Fridman, C. (2011a). Immune infiltration in human cancer: prognostic significance and disease control. Curr. Top. Microbiol. Immunol. 344, 1-24.
16. Fridman, W. H., Mlecnik, B., Bindea, G., Pagès, F., and Galon, J. (2011b). Immunosurveillance in human non-viral cancers. Curr. Opin. Immunol. 23, 272-278.
17. Galluzzi, L., and Kroemer, G. (2011). Trial watch. Monoclonal antibodies in cancer therapy. Front. Oncol. 1.5.
18. Galluzzi, L., Vacchelli, E., Albert Matthew, L., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zucman-Rossi, J., Zitvogel, L., and Kroemer, G. (in press). Trial Watch, monoclonal antibodies in cancer therapy. Oncoimmunology.
19. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P. H., Trajanoski, Z., Fridman, W. H., and Pagès, F. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964.
20. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., Perfettini, J. L., Schlemmer, F., Tasdemir, E., Uhl, M., Génin, P., Civas, A., Ryffel, B., Kanellopoulos, J., Tschopp, J., André, F., Lidereau, R., McLaughlin, N. M., Haynes, N. M., Smyth, M. J., Kroemer, G., and Zitvogel, L. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178.
21. Gulley, J. L., and Drake, C. G. (2011). Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin. Cancer Res. 17, 3884-3891.
22. Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., Feyen, N., Martens, U. M., Beckhove, P., Gnjatic, S., Schirmacher, P., Herpel, E., Weitz, J., Grabe, N., and Jaeger, D. (2011). Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prog-nostic for response to chemotherapy. Cancer Res. 71, 5670-5677.
23. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., and Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
24. Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., Dahut, W. L., Arlen, P. M., Gulley, J. L., and Godfrey, W. R. (2010). Overall sur-vival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099-1105.
25. Kline, J., and Gajewski, T. F. (2010). Clinical development of mAbs to block the PD1 pathway as an immuno-therapy for cancer. Curr. Opin. Investig. Drugs 11, 1354-1359.
26. Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin. R., Tu, T., Weichselbaum, R. R., and Fu, Y. X. (2009). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treat-ment. Blood 114, 589-589.
27. Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W. H., Pagès, F., and Galon, J. (2011). Histopathologic-based prognostic factors of colorectal cancers are asso-ciated with the state of the local immune reaction. J. Clin. Oncol. 29, 610-618.
28. Nardin, A., Wong, W. C., Tow, C., Molina, T. J., Tissier, F., Audebourg, A., Garcette, M., Caignard, A., Avril, M. F., Abastado, J. P., and Prévost-Blondel, A. (2011). Dacarbazine promotes stromal remodeling and lym-phocyte infiltration in cutaneous melanoma lesions. J. Invest. Dermatol. 131, 1896-1905.
29. Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., and Nakajima, Y. (2007). Clinical signifi-cance and therapeutic potential of the programmed death-1ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151-2157.
30. Pagès, F., Galon, J., Dieu-Nosjean, M. C., Tartour, E., Sautès-Fridman, C., and Fridman, W. H. (2010). Immune infiltration in human tumors: a prognos-tic factor that should not be ignored. Oncogene 29, 1093-1102.
31. Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., Liu, Y., Tang, J., Wang, S., and Fu, Y. X. (2010). The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immu-nity. Cancer Cell 18, 160-170.
32. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897.
33. Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., Morton, K. E., Laurencot, C. M., Steinberg, S. M., White, D. E., and Dudley, M. E. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557.
34. Rosenblatt, J., Glotzbecker, B., Mills, H., Vasir, B., Tzachanis, D., Levine, J. D., Joyce, R. M., Wellenstein, K., Keefe, W., Schickler, M., Rotem-Yehudar, R., Kufe, D., and Avigan, D. (2011). PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34, 409-418.
35. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., and Iacopetta, B. (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27, 186-192.
36. Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., and Smyth, M. J. (2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. U.S.A. 108, 7142-7147.
37. Tartour, E., Blay, J. Y., Dorval, T., Escudier, B., Mosseri, V., Douillard, J. Y., Deneux, L., Gorin, I., Negrier, S., Mathiot, C., Pouillart, P., and Fridman, W. H. (1996). Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J. Clin. Oncol. 14, 1697-1703.
38. Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., Badoual, C., Tedgui, A., Fridman, W. H., and Oudard, S. (2011). Angiogenesis and immunity: a bidirectional link potentially rel-evant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combina-tion with immunotherapy. Cancer Metastasis Rev. 30, 83-95.
39. Taylor, C., Hershman, D., Shah, N., Suciu-Foca, N., Petrylak, D. P., Taub, R., Vahdat, L., Cheng, B., Pegram, M., Knutson, K. L., and Clynes, R. (2007). Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13, 5133-5143.
40. Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W. H., Pagès, F., and Galon, J. (2011). Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 71, 1263-1271.
41. Waldmann, T. A. (2006). Effective cancer therapy through immunomodulation. Annu. Rev. Med. 57, 65-81.
42. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., and Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434.
43. Yuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., Panageas, K. S., Ritter, G., Sznol, M., Halaban, R., Jungbluth, A. A., Allison, J. P., Old, L. J., Wolchok, J. D., and Gnjatic, S. (2011). Integrated NY-ESO-1 antibody and CD8+ T-cell responses cor-relate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl. Acad. Sci. U.S.A. 108, 16723-16728.
44. Zitvogel, L., Apetoh, L., Ghiringhelli, F., and Kroemer, G. (2008). Immunological aspects of cancer chemo-therapy. Nat. Rev. Immunol. 8, 59-73.
45. Zitvogel, L., Kepp, O., and Kroemer, G. (2011). Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8, 151-160.